1. Home
  2. NGNE vs CD Comparison

NGNE vs CD Comparison

Compare NGNE & CD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$27.00

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

CD

Chaince Digital Holdings Inc. Ordinary Shares

N/A

Current Price

$5.18

Market Cap

284.2M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
NGNE
CD
Founded
2003
2011
Country
United States
United States
Employees
N/A
11
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
327.8M
284.2M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
NGNE
CD
Price
$27.00
$5.18
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$63.57
N/A
AVG Volume (30 Days)
138.7K
85.1K
Earning Date
05-08-2026
08-31-2023
Dividend Yield
N/A
N/A
EPS Growth
0.93
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.78
$3.09
52 Week High
$37.27
$14.10

Technical Indicators

Market Signals
Indicator
NGNE
CD
Relative Strength Index (RSI) 64.63 54.36
Support Level $19.40 $4.53
Resistance Level $29.05 $6.39
Average True Range (ATR) 1.86 0.52
MACD 0.53 0.11
Stochastic Oscillator 78.73 58.04

Price Performance

Historical Comparison
NGNE
CD

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About CD Chaince Digital Holdings Inc. Ordinary Shares

Chaince Digital Holdings Inc is digital fintech company providing access to the growing AI-powered infrastructure, blockchain, and digital assets. Its three core business lines include: blockchain and digital asset solutions, AI and HPC infrastructure, developing liquid cooling solutions for AI data centers and comprehensive financial services through Chaince Securities,LLC a FINRA-registered broker-dealer, and RIA.

Share on Social Networks: